Pediatric atopic dermatitis (AD) is one of the most common skin conditions encountered by health-care providers caring for infants, children, and adolescents. Pediatric patients with AD may present with other allergic and nonallergic comorbidities that require appropriate treatment and referral. They may also experience a trajectory of allergic diseases known as the atopic march, which depends on a complex interaction between genetic and environmental factors and likely involves early epidermal barrier dysfunction. Here we provide a review and clinical recommendations on the assessment and referral of comorbidities in pediatric AD.
symptoms follow the trajectory profile of the atopic march, in which early AD and wheeze are followed by rhinitis. 4 The atopic march depends on a complex interaction between genetic and environmental factors, and likely involves early epidermal barrier dysfunction. 1 There are several risk factors for multiple atopic comorbidities, including increased AD severity and persistence, earlier age of onset, parental atopic history, polysensitization, nonrural environment, and filaggrin gene mutations. 5 
Food Allergy
Food allergy is a symptomatic response triggered by food ingestion, inhalation, and/or skin contact. It involves a large range of symptoms that are usually of immediate onset including skin (eg, urticaria and angioedema), gastrointestinal (eg, vomiting and abdominal pain), and respiratory (eg, shortness of breath and wheezing). 6 Pediatric AD patients have a high likelihood of developing food allergy, with AD usually developing first. There is a strong association between AD, food sensitization (antibody response), and food allergy (symptomatic response), 7 with early-onset, severe, and persistent AD implicated as significant risk factors for food allergy in pediatric patients. 7, 8 Food sensitization early in life is positively associated with infantile AD, childhood wheeze/asthma, and allergic rhinitis. 9 Up to 66% of infants with AD have food sensitization, and up to 40% of children with AD have food allergy, 8, 10 with egg, peanut, and milk being the most common food allergens. 7 In populationbased studies, food sensitization in early-onset (≤3 months) AD was almost 6 times higher in children with the most severe AD compared to controls at 6 and 12 months of age. 10 Early onset (≤6 months) of AD was also significantly associated with sensitization to food at 18 months. 11 Importantly, food and allergen sensitization can occur epicutaneously through an impaired skin barrier, even before food ingestion, implicating the role of impaired barrier function in allergy development. 12 Despite the high incidence of food allergy in pediatric AD patients, routine allergy testing to food is not recommended for those who do not have a history of symptoms suggestive of immediate hypersensitivity reactions such as urticaria, angioedema, and airway symptoms as it can lead to false positives and misinterpretation of results. When indicated, recommended allergen testing includes skin prick testing and/or serologic assays for food-specific immunoglobulin E (IgE) antibodies, which should be performed and interpreted by an appropriate specialist. 13, 14 It is important to note that food-specific IgG testing is not a validated tool for diagnosing food allergies. The presence of food-specific IgG is expected in normal, healthy patients; therefore, there is no evidence to support the use of this test in patients with suspected food allergy. 13, 15 Food avoidance and elimination diets are not recommended in the absence of symptoms of food allergy. This group supports the joint Canadian Pediatric Society (CPS) and Canadian Society of Allergy and Clinical Immunology statement for allergy prevention in high-risk infants, which recommends not delaying the introduction of any specific solid food beyond 6 months of age. 16 The current CPS position statement, updated February 2019 at the time of this publication, includes a recommendation to introduce common allergenic solids like egg and peanut from 4 to 6 months of age in infants with AD. This document should be referred to for more specific guidance on food introduction ( www. cps. ca/ en/ documents/ position/ allergenic-solids).
Allergic Respiratory Disease
Patients with AD in early infancy and childhood, early allergic sensitization, and parental history of atopy are at increased risk of allergic respiratory disease, including asthma and rhinoconjunctivitis. 3, 17 In particular, early-onset AD is associated with increased risk of sensitization to inhalant allergens. 3 For infants and children with AD, the risk of developing respiratory allergy later in life ranges from 50% to 80%. 3, 18 This increased risk appears to be augmented by increased AD severity. 19 Approximately 20% of children with mild AD develop asthma, compared to more than 60% of children with severe AD. 17 Filaggrin mutations, known to play a role in AD skin barrier impairment, are also a risk factor for asthma development in patients with a prior diagnosis of AD. 17 Earlier-onset (≤3 months) AD is associated with increased risk of asthma at 6 years as compared to later onset. 20 Pediatric AD is also associated with increased asthma severity and persistence into adulthood. 1 Importantly, early-onset (≤2 years) AD and allergic rhinitis appear to be risk factors for AD persistence beyond 14 years of age. 18 Assessment for allergic respiratory disease in pediatric patients with AD should be considered where appropriate, including referrals for asthma assessment in children over 6 years old who fail to achieve control despite correct use of inhalers, and where diagnosis is unclear. 21 Although inhalant allergy testing is not commonly pursued in children, it may be considered in pediatric patients with relevant history, including persisting asthma symptoms with no spontaneous improvement of AD in the summer period despite the use of topical steroids. 22 
Ocular Comorbidities
Ocular comorbidities are common in patients with AD, with eye or eyelid involvement occurring in 20% to 43% of adult patients. 23, 24 These include keratoconjunctivitis, dry eye syndrome, blepharitis, conjunctivitis, cataracts, infectious keratitis, steroid-induced glaucoma, keratoconus, tear dysfunction, and inflammatory ocular conditions. 23, 25 Atopic keratoconjunctivitis (AKC) is the most severe specific ocular complication of AD, which is more common in adults than children and can lead to blindness. 24, 26 By definition, AKC in children involves the presence of severe allergic conjunctivitis with AD that is diagnosed before 16 years of age, and may also be accompanied by conjunctival hyperemia with eczema, madarosis, and blepharitis. 27 Early recognition and appropriate management of ocular comorbidities are important to prevent long-term sequelae and disability. Health-care providers (HCPs) should recognize signs and symptoms that require referral or urgent care such as photophobia, pain, blurry vision, decreased extraocular movements, and hyphema. Herpetic keratoconjunctivitis should be ruled out in children with eczema herpeticum, especially on facial sites. 28 
Eosinophilic Esophagitis
AD is associated with increased risk of subsequent diagnosis of eosinophilic esophagitis (EoE). EoE is a chronic allergic inflammatory disease that can be triggered by specific foods, and may be considered a late manifestation of the atopic march with a peak age of onset of 2.6 years. 29 This is later than the peak age of onset of AD, food allergy, asthma, and allergic rhinitis, which is 0.3, 1, 1.1, and 2.1 years, respectively. 29 In a case-control study of 449 patients, 46% of patients with EoE had AD, and EoE was associated with a personal and family history of atopy. 30 Symptoms in infants and young children include feeding difficulties, failure to thrive, and gastroesophageal reflux. School-aged children may present with vomiting, abdominal pain, and regurgitation; adolescents and adults with dysphagia and food impaction. 31 HCPs should be aware of the increased risk for EoE in pediatric AD patients and ensure appropriate interdisciplinary management if symptomatic.
Nonatopic Comorbidities of Pediatric AD

Allergic Contact Dermatitis
Allergic contact dermatitis (ACD) is common in patients with AD. Contact sensitization occurs in up to half of pediatric patients with AD, 32, 33 with up to one-third diagnosed with ACD. 33 Due to the complex interplay between concomitant atopic skin diseases, ACD is underdiagnosed in pediatric patients with AD. 34 In some instances, over-the-counter and natural skin products that are used to treat AD may contribute to the development of contact dermatitis. Although the literature on the topic is scarce, our group aligns with this clinical observation, and recognizes the importance of this consideration given the impaired skin barrier and potential for allergic sensitization. A recent review of natural oils for treating AD in pediatric patients highlighted the potential of olive oil to cause irritant and ACD. 35 One study of 1142 patch tests in children (<18 years old) revealed that pediatric patients with AD showed significant reaction patterns to allergens notable for their use in dermatologic products, including cocamidopropyl betaine, lanolin, tixocortol pivalate, and parthenolide. 36 Other examples of sensitizers that can be found in products used by AD patients include tea tree oil (melaleuca), coconut oil, chamomile, and other various botanicals. HCPs should be aware of the potential of certain skin care ingredients to exacerbate AD symptoms, and assess for ACD appropriately in patients with AD, especially in those with an unusual distribution/pattern of disease, or whose disease remains severe despite adequate therapy and good adherence to treatment.
Psychosocial Comorbidities
Pediatric AD is associated with an increased risk of several mental health conditions including attention-deficit/hyperactivity disorder (ADHD), anxiety, and depression. 37 Atopic individuals have a 30% to 50% greater chance of developing ADHD compared to controls. 38 Interestingly, the early use of sedating antihistamines in pediatric patients with AD is correlated with a risk of ADHD symptoms. 39 In a Taiwanese insurance database study, allergic disorders including AD were more common in patients diagnosed with ADHD. 40 Children with behavioural or learning difficulties should be referred for assessment.
Other studies using this database found that adolescent AD increased the risk of having major depression, any depressive disorder, and anxiety disorders later in life. 41 Two recent systematic reviews showed an association between AD and depression in both children and adults, and between pediatric AD and parental depression. 42, 43 Anxious youth with atopy exhibit more overall and generalized anxiety symptoms relative to nonatopic youth. 44 Therefore, screening and appropriate referral for both anxiety and depression are important. Validated diagnostic tools may be used to screen for depression, such as the Patient Health Questionnaire 2 (PHQ-2), or the Sleep, Interest, Guilt, Energy, Concentration, Appetite, Psychomotor, and Suicidality (SIGECAPS) criteria. SIGECAPS is a tool that diagnoses depression if 4 of 8 depressive symptoms in combination with depressed mood are present for at least 2 weeks. 45 Screening is particularly important in the presence of risk factors including increasing AD severity, female sex, and increasing age; however, these risk factors are based primarily on adult studies and risk factors for depression in pediatric AD have not been studied extensively. 45 Suicidal ideation and attempted suicide are also increased in adolescents with AD; however, few studies have looked at the risk of completed suicide in this age group. 42, 46 Screening for suicidal ideation should be done in patients with AD, with appropriate mental health referrals when necessary.
Sleep disturbance is very common in patients with AD and is a major factor leading to impaired quality of life (QoL). 47 Sleep disturbance impacts psychosocial domains in AD and likely has a negative impact on school performance, social functioning, and family functioning. Importantly, sleep is a relevant functional outcome and should be assessed to determine AD burden and response to therapy.
Recognition of QoL and psychosocial impacts allows medical providers to address and alleviate these impacts preemptively. Optimal AD management and family education may improve treatment adherence, treatment outcomes, and QoL. In one study, parents with a greater understanding of a child's individual treatment plan reported higher QoL. 48 Patient and parent pre-emptive counseling to address issues related to disease impact before they arise may lower parental stress and potentially improve outcome. A Cochrane review of psychological and educational interventions for pediatric AD highlighted that psychoeducational interventions can improve disease severity and QoL. 49 
Growth Impairments
Limited data suggest that most children with AD do not have constitutional growth delay. 50 However, there is some evidence that children with severe AD may have decreased growth velocity as they approach the teenage years. This phenomenon is temporary and not persistent into adulthood. [50] [51] [52] The mechanism for this decreased growth velocity is not known; however, insufficient sleep has been suggested as an indicator. 52 Prolonged treatment with topical corticosteroids does not seem to contribute to growth impairment. 51 Growth impairment in AD should be recognized by HCPs treating this disease.
Cardiovascular Risk Factors
The association between AD and cardiovascular (CV) disease is controversial. Although a link between AD and CV risk has been identified in some adult cohorts, 52, 53 the risk to the pediatric population is unknown. One Asian study reported an increased risk of ischemic stroke in adults with AD 54 ; however, this relationship has not been replicated in European databases. 55 Findings from a Danish database study of adolescents with AD suggest that increased CV risk may be related to lifestyle factors rather than the inflammatory nature of AD. 56 One case-controlled study from the United States showed that moderate-to-severe pediatric and adolescent AD may be associated with a higher risk of central obesity and hypertension 57 ; however, a subsequent database study, which did not assess AD severity, showed higher risk of obesity but not hypertension, hyperlipidemia, or diabetes. 58 A meta-analysis of 30 studies showed a significant association between both adult and pediatric AD and being overweight and/or obese in North America and Asia, but not in Europe. 59 There is no evidence to recommend routine screening for metabolic syndrome in children with AD, but HCPs should recognize that a potential association exists.
Autoimmune Disease
Other autoimmune phenomena may be associated with pediatric AD based on preliminary observations. These include vitiligo, 60 alopecia areata, 60 thyroid autoimmunity, 61 rheumatoid arthritis, 62 inflammatory bowel disease, 62 irritable bowel syndrome, 63 and celiac disease. 64 A detailed history including other dermatologic issues, symptoms of thyroid dysfunction, joint pain, and bowel symptoms may be appropriate in children with AD. Routine serological screening and referral is not recommended and should be done based on clinical history.
Conclusions
Pediatric patients with AD may present with or develop both atopic and nonatopic comorbidities. HCPs should be aware of these conditions and ensure appropriate multidisciplinary management where appropriate. Atopic comorbidities are more common in severe and early-onset AD, and include food allergy, asthma, allergic rhinoconjunctivitis, and EoE. Nonatopic comorbidities that should be screened for include anxiety, depression, and ADHD.
